CNS Pharmaceuticals, Inc. Accrued Liabilities, Current
CNS Pharmaceuticals, Inc. (CNSP) had Accrued Liabilities, Current of $260.14 thousand as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Balance Sheet › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2023-08-14
- 2023-06-30: Accrued Liabilities, Current $260.14K.
- 2023-03-31: Accrued Liabilities, Current $853.23K.
- 2022-12-31: Accrued Liabilities, Current $828.39K.
- 2022-09-30: Accrued Liabilities, Current $200.00K.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2023-06-30 | $260.14K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $853.23K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $828.39K 10-Q · filed 2023-08-14 |
| 2022-09-30 | $200.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $276.57K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $307.01K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $224.95K 10-K · filed 2023-03-31 |
| 2021-09-30 | $901.22K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $760.68K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $534.94K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $519.80K 10-K · filed 2022-03-03 |
| 2020-09-30 | $260.60K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $110.69K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $144.79K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $21.50K 10-K · filed 2021-02-12 |
| 2019-09-30 | $46.07K 10-Q · filed 2019-12-20 |
| 2018-12-31 | $23.60K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |